Table 2. Correlations of B_M assay results with peak serologic responses^a.

	Day 0		Day 28
	ρ^c	p^c	ρ^c	p^c
LPS (n = 8)^b
SFC/10⁶ expanded cells	0.51	0.2	0.95	0.0003
SFC/total IgG⁺	0.55	0.2	0.95	0.0003
SFC/CD19⁺	0.52	0.2	0.90	0.002
SFC/CD19⁺ CD27⁺	0.55	0.2	0.90	0.002
SFC/CD19⁺ CD27⁺ IgG⁺	0.55	0.2	0.93	0.001
IpaB (n = 5)^b
SFC/10⁶ expanded cells	0.67	0.2	0.67	0.2
SFC/total IgG⁺	0.67	0.2	0.8	0.1
SFC/CD19⁺	0.67	0.2	0.8	0.1
SFC/CD19⁺ CD27⁺	0.67	0.2	0.8	0.1
SFC/CD19⁺ CD27⁺ IgG⁺	0.67	0.2	0.8	0.1

Statistically significant differences (p < 0.05) are bolded.

Only recipients of CVD 1204 and CVD 1208 who mounted a fourfold or higher rise of anti-LPS IgG pre- to post-vaccination and had evidence of appropriate B_M expansion in vitro were included in this analysis. In these volunteers anti-LPS and anti-IpaB SFC were adjusted for defined B subpopulations and correlated with the corresponding peak antigen-specific serological response before and after immunization.

Flow cytometry data available for 8/9 LPS seroresponders and 5/7 IpaB seroresponders.

Determined by Spearman ρ comparing B_M response to peak serum titer.

Table 2. Correlations of BM assay results with peak serologic responsesa.

Table 2. Correlations of B_M assay results with peak serologic responses^a.